Our immune system defends us from harmful bacteria and viruses, but, if left unchecked, the cells that destroy those invaders can turn on the body itself, causing auto-immune diseases like type-1 diabetes or multiple sclerosis.
A molecule called insulin-like growth factor-1 (IGF-1) boosts the body’s natural defence against this ‘friendly fire’, scientists at the European Molecular Biology Laboratory (EMBL) in Monterotondo, Italy, have found. The findings, published today in EMBO Molecular Medicine, are especially exciting because IGF-1 is already approved for use in patients, which could speed up the move to clinical trials for treating auto-immune diseases.
“To me what was really striking was the survival rate for multiple sclerosis,” says Daniel Bilbao, who conducted the research with Nadia Rosenthal’s lab at EMBL, “we went from less than 50% survival in untreated animals to over 80% survival in animals that received IGF-1.”
In patients with auto-immune diseases, a group of cells called pro-inflammatory T-effector cells become sensitized to specific cells in the body, identifying them as foreign and attacking them as if they were invading bacteria. If this misdirected attack targets the insulin-producing cells in the pancreas, the result is diabetes; if it affects myelin-sheathed cells in the central nervous system, the person suffers from multiple sclerosis.
These attacks on the body’s own cells go unchecked due to the failing of another type of immune cell: T-regulatory (T-reg) cells, which, as their name implies, control T-effector cells, shutting them down when they are not needed.
Working with then PhD student Luisa Luciani, Bilbao and Rosenthal found that, if mice with conditions that mimic type-1 diabetes and multiple sclerosis received IGF-1, they started producing more T-reg cells where they were needed – the pancreas and the central nervous system, respectively – and the disease was suppressed. The scientists went on to test IGF-1’s effects on T-reg cells taken from both mice and humans, confirming that IGF-1 acts directly on T-reg cells – rather than indirectly by affecting some other factor that induces T-reg cells to multiply.
In a separate study published earlier this year, Bilbao and Rosenthal had found that IGF-1 has the same effect on another condition in which the immune system goes awry. They found that allergic contact dermatitis, an inflammatory skin disease thought to affect as many as one in five Europeans, is also suppressed in mice by treating them with IGF-1.
“These studies have real clinical significance, because IGF-1 is already an approved therapeutic, which has been tested in many different settings, so it will be much easier to start clinical trials for IGF-1 in auto-immune and inflammatory diseases than it would if we were proposing a new, untested drug,’ says Nadia Rosenthal, former Head of EMBL Monterotondo, and currently at Imperial College London, UK, and Monash University, Australia, where she is Scientific Head of EMBL Australia.
“My hope and goal is to now see this applied to humans, but – as with everything – that will depend on funding,” Bilbao adds. Rosenthal is planning to further explore the role of IGF-1 in inflammation and regeneration, and its potential for treating conditions such as muscular atrophy, fibrosis or heart disease.
Published online in EMBO Molecular Medicine on 22 October 2014. For images and more information please visit: www.embl.org/press/2014/141022_Monterotondo.
Policy regarding use EMBL press and picture releases including photographs, graphics and videos are copyrighted by EMBL. They may be freely reprinted and distributed for non-commercial use via print, broadcast and electronic media, provided that proper attribution to authors, photographers and designers is made.
Sonia Furtado Neves EMBL Press Officer & Deputy Head of Communications Meyerhofstr. 1, 69117 Heidelberg, Germany Tel.: +49 (0)6221 387 8263 Fax: +49 (0)6221 387 8525 email@example.com http://s.embl.org/press
Sonia Furtado Neves | EMBL Research News
Single-stranded DNA and RNA origami go live
15.12.2017 | Wyss Institute for Biologically Inspired Engineering at Harvard
New antbird species discovered in Peru by LSU ornithologists
15.12.2017 | Louisiana State University
A study carried out by an international team of researchers and published in the journal Physical Review X shows that ion-trap technologies available today are suitable for building large-scale quantum computers. The scientists introduce trapped-ion quantum error correction protocols that detect and correct processing errors.
In order to reach their full potential, today’s quantum computer prototypes have to meet specific criteria: First, they have to be made bigger, which means...
Since 2016, German and Spanish researchers, among them scientists from the University of Göttingen, have been hunting for exoplanets with the “Carmenes”...
DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.
Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...
MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.
Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...
Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
18.12.2017 | Information Technology
18.12.2017 | Physics and Astronomy
18.12.2017 | Agricultural and Forestry Science